Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

October 19, 2020

Study Completion Date

October 19, 2020

Conditions
Inflammatory Bowel Diseases
Interventions
BIOLOGICAL

Urine and stoll samples

Urine collection will be proposed to patient during consultations or medical examinations corresponding to routine care of patients with IBD at the time of prescribing a FC test. The urine sample, as for stool samples, will be collected in an ordinary universal container at any time of the day (no dietary restriction is required). Urine and stool samples should be taken during the same period (for example, the same day, or within a maximum of one week if no change in treatment)

Trial Locations (1)

92110

Service de biochimie clinique - Hôpital Beaujon, Clichy

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT05171452 - Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter